Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT
January 26, 2023 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
January 18, 2023 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
December 12, 2022 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial
November 16, 2022 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments
November 10, 2022 08:00 ET
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 Interim Analysis on Track for Q1 2023Camsirubicin Clinical Data at CTOS 2022 Next WeekMNPR-202 Preclinical Data at ASH 2022 in December WILMETTE, Ill., Nov. 10, 2022 (GLOBE...
Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
October 27, 2022 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting
October 19, 2022 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
October 12, 2022 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
October 05, 2022 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar to Present at Roth Inaugural Healthcare Opportunities Conference
September 28, 2022 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...